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Introduction
A paradigm shift occurred in the past decade in the treatment 
of lung cancer with the use of targeted agents which improved 
significantly the survival of patients. Major contributor 
to these changes was the development of molecular 
classification of lung cancer and of the adenocarcinoma 
subgroup in particular. In parallel, a quality assured molecular 
diagnostic system was developed in the majority of countries 
accompanied by the development of reimbursement 
schemes. It seems that this development is continuous where 
each participant from clinicians to the pathologist have to 
continuously accomodate to new requirements. 
Cancer sampling from the point of pathologist
Pathological diagnostics of lung cancer is still based on 
biopsies or cytology since only a small minority of cases 
can be surgically removed (20%) (Figure 1). These types of 
tumor sampling providing small tissues or limited amount 
of cells represent a major challenge for pathologists and 
the type of tumor sampling chosen by the bronchologists 
has a major impact on the quality of diagnosis. With recent 
changes in the classification of lung adenocarcinoma, the 
required differential diagnostic protocols requires increased 
amount of tumor tissues for ancillary techniques such as 
immunohistochemistry (1). The extended use of these 
techniques on the other hand defines the minimal amount of 
tissue necessary for diagnosis. Recent guidelines suggest to 
minimise the use of cytology replacing with biopsies when 
diagnosing lung cancer which can provide more appropriate 
material for differential- and molecular diagnostics (2). 
Single sampling of lung cancer is an insufficient, inadequate 
mode of sampling. In case of biopsies multiple sampling is 
the requirement (minimum of 4) while in case of cytology 
cell-block technique must be applied. It is evident that the 
application of cell-block technique requires more cells as 
compared to simple smear but provides more diagnostic 
opportunities. Sampling of progressing tumor from 
mediastinal lymph nodes or from pleural or other effusions 
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are more and more frequently possible providing invaluable 
material for diagnostics where cytology combined with cell-
blocks can be appropriate as compared to biopsy. There are 
two important issues which must be cleared for oncologist 
and molecular pathologist. There is a predetermined 
minimal cell number requirement for ancillary techniques 
[immunohistochemistry, molecular diagnostics, fluorescent 
in situ hybridisation (FISH)] and the tumor cell to normal 
cell ratio of the sample provides a threshold or cut off 
value for these techniques (3). Accordingly, the primary 
histopathological diagnosis must provide information for 
the clinician whether the remaining tissue/cell number is 
sufficient and/or adequate for further molecular testing. 
EGFR/KRAS mutational analysis
The most frequent molecular alterations in lung 
adenocarcinoma are KRAS- (30%) and EGFR-mutation 
(10-15%) where the minimally required DNA is 5 ng 
equal to 1,000 cells (3). It would be optimal to provide 
FFPE materials right at the primary sectioning of the 
tumor biopsies but the milieu must be than molecular 
pathologically strictly defined avoiding contamination, 
allowing microdissection of tumor area providing nuclease-
free environment. Since the sensitivity of the applied 
molecular techniques is different, the tumor-normal cell 
ratio is critical (Table 1). Sensitivity of various methods is 
between 1-20% suggesting the minimal tumor cell normal 
cell ratio in the sample. The most sophisticated next 
generation sequencing technologies can go fare bellow 
the sensitivity of previous techniques but for diagnostic 
purposes they have to be set for 5% threshold rate. 
However, guidelines suggest not to do molecular testing 
below 10% T/N ratio due to the increased chance of false 
results (4,5).
ALK/ROS1 translocations
Recent molecular studies identified that ALK translocations 
occur in lung adenocarcinoma with an estimated frequency 
of 5% and ROS1 translocation with an estimated frequency 
of 1%. Both genetic alterations provide a cancer with a 
constitutively active tyrosine kinase as a driver oncogene. 
Lung cancers with such genetic alterations are sensitive to 
ALK or ROS1 inhibitors. Detection of these translocations 
can be done by using multiplex PCR or sequencing but 
require fresh samples and RNA. In routine diagnostics of lung 
cancer these gene translocations are detected by FISH. These 
tests can be done on FFPE sections which must contain 
at least 100 cancer cells where the threshold for positivity 
is 15% (4). These FISH tests are validated for histological 
sections and not for cytological smears. Meanwhile it can be 
attempted to perform these tests on cytology samples but the 
negativity of the result does not exclude the possibility that 
A B C
Figure 1 Pathology sample types of lung cancer. (A) Surgical resection specimen. Pathology work-up, paraformaldehyde fixation, 
paraffin embedding, HE staining (20×); (B) transbronchial biopsy. Paraformaldehyde fixation, whole sample embedding to paraffin, 
immunohistochemistry for EGFR (40×). Note the normal surface epithelium and a minimal amount of stromal tumor cell clusters; (C) 
cytology smear. Paraformaldehyde fixation, HE staining (100×). Note the tumor cell rich area. 
Table 1 Tumor-normal cell ratio and the EGFR mutation 
diagnostics: technology is the issue?
Technology Quiagen (%) Cobas (%) Sanger (%)
Sensitivity 1 5 20
T/N ratio
1:0 (rare) 1 5 20
1:1 2 10 40
1:5 5 25 100 (rare) 
1:10 10 50 NA
Data represent the minimal % of mutant tumor cells detectable 
by the technology.
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the tumor contains translocated genes. However, unlike in 
case of molecular diagnostics of EGFR- or KRAS-mutations, 
stained cytology smears are not acceptable for FISH testing. 
Recently various immunohistochemical tests were developed 
to detect ALK or ROS1 proteins in lung adencarcinoma, 
which serve as a screening technology for negativity where 
no further analysis necessary by FISH (4,5). However, none 
of these immunohistochemical tests are validated on cytology 
smears. 
Sequential testing: pros and cons
An extended molecular  diagnost ic  panel  of  lung 
adenocarcinoma is a timely procedure extending the 
primary diagnosis period considerably. Molecular testing 
can be only applied on lung cancer when the primary 
diagnosis is correct. It is another factor that frequently the 
primary diagnosis of lung cancer and its molecular analysis 
are performed in different laboratories adding further delay 
in providing the necessary information for clinician. 
In developed countries where the reimbursement 
and capacity of molecular testing of lung cancer is 
provided reflex testing is possible cutting back the turn 
around time significantly. However in countries where 
the reimbursement is inadequate and/or the capacity is 
inappropriate sequential performance of molecular testing 
can be justified. These protocols consider the rank of 
incidence of various molecular alterations and start it 
with the most frequent one such as KRAS in Caucasian 
and EGFR in Asian patients, eliminating a significant 
proportion of samples from further work-up since driver 
mutations are exclusive in lung cancer (Figure 2). With such 
a selection hit rate for EGFR mutation can be elevated 
up to 20% in Caucasians and hit rate can be doubled for 
ALK mutant patients. In parallel IHS screening for ALK 
or ROS1 negative lung cancer can be performed. These 
three analyses can select out a reasonably low proportion of 
lung adenocarcinomas where the FISH testing for ALK or 
ROS1 translocations must be performed. The application of 
sequential molecular testing of lung cancer can reduce the 
volume and cost of analysis approximately by 30%. 
Conclusions
Unlike in case of most solid cancer types, availability of 
appropriate tumor tissues for differential diagnosis and 
molecular pathology examinations is a major limiting factor 
in lung cancer. Tissue biopsy must be the gold standard 
in sampling lung cancer excluding cytology as much as 
possible. The requirements of pathological diagnosis and 
molecular testings can guide the sampling clinician to 
provide appropriate tumor tissue where the tumor cell- 
normal cell ratio could affect the choise of techniques of 
various sensitivities. 
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